Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 5:11:388.
doi: 10.3389/fimmu.2020.00388. eCollection 2020.

IDO and Kynurenine Metabolites in Peripheral and CNS Disorders

Affiliations
Review

IDO and Kynurenine Metabolites in Peripheral and CNS Disorders

Yi-Shu Huang et al. Front Immunol. .

Abstract

The importance of the kynurenine pathway in normal immune system function has led to an appreciation of its possible contribution to autoimmune disorders such as rheumatoid arthritis. Indoleamine-2,3-dioxygenase (IDO) activity exerts a protective function, limiting the severity of experimental arthritis, whereas deletion or inhibition exacerbates the symptoms. Other chronic disorder with an inflammatory component, such as atherosclerosis, are also suppressed by IDO activity. It is suggested that this overall anti-inflammatory activity is mediated by a change in the relative production or activity of Th17 and regulatory T cell populations. Kynurenines may play an anti-inflammatory role also in CNS disorders such as Huntington's disease, Alzheimer's disease and multiple sclerosis, in which signs of inflammation and neurodegeneration are involved. The possibility is discussed that in Huntington's disease kynurenines interact with other anti-inflammatory molecules such as Human Lymphocyte Antigen-G which may be relevant in other disorders. Kynurenine involvement may account for the protection afforded to animals with cerebral malaria and trypanosomiasis when they are treated with an inhibitor of kynurenine-3-monoxygenase (KMO). There is some evidence that changes in IL-10 may contribute to this protection and the relationship between kynurenines and IL-10 in arthritis and other inflammatory conditions should be explored. In addition, metabolites of kynurenine downstream of KMO, such as anthranilic acid and 3-hydroxy-anthranilic acid can influence inflammation, and the ratio of these compounds is a valuable biomarker of inflammatory status although the underlying molecular mechanisms of the changes require clarification. Hence it is essential that more effort be expended to identify their sites of action as potential targets for drug development. Finally, we discuss increasing awareness of the epigenetic regulation of IDO, for example by DNA methylation, a phenomenon which may explain differences between individuals in their susceptibility to arthritis and other inflammatory disorders.

Keywords: 3-hydroxyanthranilic acid; Huntington's disease; T-cells; arthritis; kynurenine; lymphocyte antigens.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Summary of the major compounds and enzymes of the kynurenine pathway. ACMSD is α-amino-β-carboxymuconate semialdehyde decarboxylase. In cells lacking this enzyme the molecule in parentheses (ACMS) rearranges spontaneously (non-enzymatically) to quinolinic acid. When present, ACMSD converts ACMS to picolinic acid. Key metabolites include (A) Tryptophan, (B) Kynurenine, (C) Kynurenic acid, (D) Anthranilic acid, (E) 3-hydroxy-kynurenine, (F) 3-hydroxy-anthranilic acid, (G) 5-hydroxy-anthranilic acid, (H) ACMS, (I) xanthurenic acid, (J) picolinic acid, and (K) quinolinic acid.
Figure 2
Figure 2
Cell-specific IDO pathways in inflammation. (A) In the immune system, APCs upregulate expression of the complete IDO pathway when activated. Tolerogenic APCs promote the differentiation of Tregs and inhibit Th17 differentiation. Tregs inhibit APC activation via CTLA-4, which also inhibits differentiation of pre-osteoclasts (pOCL) to osteoclasts (OCL); soluble CTLA4-Ig (ipilimumab) also inhibits OCL differentiation. Conversely, Th17 promote osteoclastogenesis. (B) In the CNS, microglia express low levels of kynurenine aminotransferase, pushing the IDO pathway to the production of excitatory and potentially neurotoxic quinolinic acid (dashed arrow). Astrocytes express low levels of KMO which leads to the accumulation of the NMDA receptor blocker and neuroprotective kynurenic acid (full arrows). See Figure 1 for legend to IDO pathway metabolites.

Similar articles

Cited by

References

    1. Yoshida R, Imanishi J, Oku T, Kishida T, Hayaishi O. Induction of pulmonary indoleamine 2,3-dioxygenase by interferon. Proc Nat Acad Sci USA. (1981) 78:129–32. 10.1073/pnas.78.1.129 - DOI - PMC - PubMed
    1. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, et al. . Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. (1998) 281:1191–3. 10.1126/science.281.5380.1191 - DOI - PubMed
    1. Mellor AL, Munn DH. Immunology at the maternal-fetal interface: lessons for T cell tolerance and suppression. Ann Rev Immunol. (2000) 18:367–91. 10.1146/annurev.immunol.18.1.367 - DOI - PubMed
    1. Stone TW, Perkins MN. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol. (1981) 72:411–2. 10.1016/0014-2999(81)90587-2 - DOI - PubMed
    1. Perkins MN, Stone TW. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. (1982) 247:184–7. 10.1016/0006-8993(82)91048-4 - DOI - PubMed

Publication types

MeSH terms

Substances